Technology Convergence to Improve Patient Healthcare Outcomes
This research service provides an understanding of the significance and impact of digital therapeutics on the emerging applications. Digital therapeutics is evidence-based therapeutic intervention for prevention, management, and treatment of a specific disease condition; it has the potential to address needs that traditional treatments and therapies have not been able to meet.
Following the COVID-19 public health emergency, the adoption of virtual care technologies has grown, particularly in the field of behavioral health. This research service focuses on the emerging applications for digital therapeutics in the treatment of cancer and neurodegenerative diseases, and in physical therapy. The study offers an overview of technologies enabling digital therapy and companies to action in the fields of oncology, physical therapy, and neurodegenerative disease management. R&D and partnership activities are also discussed. Patent analysis and growth opportunities for stakeholders developing digital therapeutics are also covered.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Voluntis, France
- Kaiku Health (a part of Elekta), Finland
- Prosoma, UK
- NeuroGlee Therapeutics, Singapore
- Cognito Therapeutics, US
- Kaia Health